Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
Date:11/1/2013

NANJING, China, Nov. 1, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing / Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.845.675.0437China Domestic toll:800.819.0121 China Domestic mobile toll:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q3 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 94745140

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.855.452.5696United States toll:+1.646.254.3697The passcode for replay participants is 94745140. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Vivien LiangCindy ZhengSimcere Pharmaceutical GroupBrunswick GroupTel: 86-25-8556-6666*8857Tel: 1-212-333-3810In Beijing: Yue Yu Brunswick Group Tel: 86-10-5960-8600
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
2. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
3. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
4. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
5. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
6. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
8. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
9. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
10. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
11. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes and ... around the nation. What do they have in common? All have been affected by ... new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... connectors, is now promoting to the US market its advanced highly customizable contact ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range ...
(Date:12/7/2016)... MI (PRWEB) , ... December 07, 2016 , ... ... and financial consultation services from offices located in South Lyon, Dewitt, Williamston, East ... benefit a basketball coach who needs treatment for a brain tumor. , Jason ...
(Date:12/7/2016)... Folsom, CA (PRWEB) , ... December 07, 2016 ... ... that provides insurance and financial consultation services to residents in the Sacramento/Folsom region, ... Choice Another Chance treatment facility. , The Another Choice Another Chance treatment center ...
Breaking Medicine News(10 mins):